-Anshul Jain The sacroiliac joint (SIJ) fusion market is experiencing explosive expansion, but for the sophisticated physician-investor, rapid growth often masks a dangerous underlying trend: commoditization. As new products flood the SIJ space—many simply wedging between the joint or crossing it with only incremental differences—a brutal pattern of downward pricing pressure and fragmentation is emerging. For surgeons allocating capital into MedTech, the investment thesis must shift from...

Are you investing in true procedural efficiency, or just financing a depreciating marketing gimmick? "Legacy MedTech wants your ASC management board to believe you cannot compete for local spine volume without a multi-million-dollar navigation robot. But when every robotic case adds 35 minutes of setup time and $1,800 in single-use proprietary disposables, who is that machine actually enriching: your facility’s bottom line, or the vendor's quarterly hardware quota?" There is a capital...

"If Wall Street is punishing inpatient-dependent conglomerates and rewarding pure-play outpatient innovators, why is your capital still tied up in legacy medical device stocks?" As August 2026 rolls in, the Q3 earnings calls from the "Big MedTech" conglomerates—Medtronic, Stryker, Zimmer Biomet, and Johnson & Johnson—are dominating the financial headlines. On the surface, corporate PR teams are touting stabilized revenues and dividend yields. But if you peel back the consolidated balance...